FDA Approves Nuzolvence, Blujepa to Treat Gonorrhea (1)

(Updates to specify the type of treatments in the first bullet.)

The FDA approved Entasis Therapeutics’ Nuzolvence (zoliflodacin) and GSK’s Blujepa (gepotidacin) to treat gonorrhea in patients 12-years an older.

• Both are considered oral medicines
  • Nuzolvence is granules that dissolve in water
  • Blujepa is oral tablets
• In separate studies, 91% of patients who took Nuzolvence were cured and 93% of patients who took Blujepa were cured
• Gave Nuzolvence and Blujepa Fast Track, Qualified Infectious Disease Product and Priority Review designations
• Blujepa was approved in March 2025 to treat urinary tract infections

To view the source of this information, ...